4.3.1 Sintesi e raccomandazioni - Biblioteca Medica

In conclusione i risultati di questa valutazione mostrano come il rapporto costo efficacia
della combinazione sia comunque decisamente elevato se confrontato con i valori di accettabilità
definiti a livello internazionale (p. es. un costo di $30.000 per anno di vita salvato [15]).
Quindi, tenendo conto dell’attuale prezzo dei farmaci, la terapia combinata pare non avere
una compatibilità economica accettabile per il nostro SSN, se non per specifici pazienti
selezionati, cioè quelli ad alto rischio di progressione. Qualora in futuro si rendessero disponibili
i dati dell’impatto della combinazione 5ARI e α 1
-litici sulla qualità di vita dei pazienti,
l’analisi dovrebbe essere rivista tenendo conto di questi risultati.
6.2.5.2. Bibliografia
1. Johnson NJ, Kirby RS. Treatments for benign prostatic hyperplasia: An analysis of their
clinical and economic impact in the United Kingdom and Italy. J Outcomes Res, 1999:
3, 11-26.
2. Lowe FC, McDaniel RL, Chmiel JJ, Hillman AL. Economic modeling to assess the costs of
treatment with finasteride, terazosin, and transurethral resection of the prostate for men
with moderate to severe symptoms of benign prostatic hyperplasia. Urology, 1995: 46,
477-483.
3. Cockrum PC, Finder SF, Ries AJ, Potyk RP. A pharmacoeconomic analysis of patients with
symptoms of benign prostatic hyperplasia. Pharmacoeconomics, 1997: 11, 550-565.
4. McConnell JD, Barry MJ, Bruskewitz RC et al Benign prostatic hyperplasia: diagnosis and
treatment. Agency for Health Care Policy and Research. Clin Pract Guide/Quick Ref
Guide Clin 1994 AHCPR Publication N 94-0582
5. Albertsen PC, Pellissier JM, Lowe FC, Girman CJ, Roehrborn CG. Economic analysis of
finasteride: A model-based approach using data from the Proscar long-term efficacy
and safety study. Clin Ther, 1999: 21, 1006-1024
6. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting
enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and
Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA, 2002:
288, 2981-97
7. Hillman AL, Schwartz JS, Willian MK, Peskin E, Roehrborn CG, Oesterling JE, Mason
MF, Maurath CJ, Deverka PA, Padley RJ. The cost-effectiveness of terazosin and placebo
in the treatment of moderate to severe benign prostatic hyperplasia. Urology, 1996:
47, 169-178
8. Lanes SF, Sulsky S, Walker AM et al A cost density analysis of benign prostatic hyperplasia
Clin Ther, 1996: 18, 993-1004
9. Oster G, Edelsberg J, Pozniak A, Thompson D. Resource utilisation and costs of treatment
with doxazosin versus tamsulosin in men with benign prostatic hyperplasia. J Outcomes
Res, 2000: 4, 31-40.
10. Baladi JF, Menon D, Otten N. An economic evaluation of finasteride for treatment of
benign prostatic hyperplasia. Pharmacoeconomics, 1996: 9, 443-454
179